NEW HAVEN, Conn.--(BUSINESS WIRE)--Kolltan Pharmaceuticals, Inc., a privately held clinical-stage company focused on the discovery and development of novel antibody-based drugs targeting receptor tyrosine kinases (RTKs), today announced results from preclinical studies using an anti-KIT monoclonal antibody to enhance T-cell checkpoint blockade in the treatment of cancer. The data are being presented in an oral session at the 30th Annual Society for Immunotherapy of Cancer (SITC) Conference, being held November 4-8 in National Harbor, Maryland. Kolltan plans to initiate clinical studies early next year for KTN0158, a selective and potent anti-KIT antibody drug candidate that targets KIT as an oncogenic tumor driver and in mast cell diseases.
Help employers find you! Check out all the jobs and post your resume.
